Own these ‘high quality compounders’ for the next 5 years, says Stephens
Stephens Research says buying and holding a select handful of stocks could help investors ride out macroeconomic shocks in the long run. The firm recently issued its “art collector list,” highlighting stocks it considers to be “high quality compounders with competitive moats, strong free cash flows, fortress balance sheets and sustainable returns on invested capital.” For this list, Stephens focused on an outlook of more than five years, given “the macro uncertainties around higher interest rates, geopolitical conflicts and an election year in the U.S.” Many of the stocks on the Stephens list have an overweight rating from their respective analysts. Stocks are on pace to end the year higher, with all three major averages having risen for seven straight weeks . So far this month, the Dow Jones Industrial Average and S & P 500 have gained nearly 4%, while the Nasdaq Composite has advanced almost 5%. Investors grew optimistic after the Federal Reserve left benchmark interest rates unchanged at its final policy meeting of 2023, and signaled three cuts in 2024. Cybersecurity firm CrowdStrike made the list. The stock has been on fire from the start of the year with a 147% gain. Analyst Brian Colley has a $255 per share price target on this stock, which implies about 2% downside from Friday’s close. CRWD YTD mountain CrowdStrike stock. “As the only publicly traded enterprise software company with LTM [last twelve months] revenue > $2B growing > 35% with 30%+ FCF [free cash flow] margins, CRWD offers a truly unique combination of industry-leading growth and FCF margins with a strong competitive moat and best-in-class unit economics,” Colley said. Coterra Energy is also on the list, with a $39 per share price target from analyst Michael Scialla, or more than 55% upside from Friday’s $25.13 close. The stock has added about 4% this year. CTRA YTD mountain Coterra Energy stock. “An early entrant in both the Marcellus and Permian Basin, CTRA established core holdings that are among the best in both regions,” Scialla said. “Based on our well analysis and state production data, the company’s drilling inventory currently generates the best returns in our natural gas peer group.” In health care, analyst Scott Fidel highlighted UnitedHealth’s “unmatched portfolio of diversified [and] vertically-integrated health platforms,” which includes its pharmacy care services unit Optum. Fidel has a $585 per share price target on the stock, or about 10% upside from Friday’s $531.12 close. Shares are about flat in 2023. UNH YTD mountain UnitedHealth stock. “UNH is the undisputed industry bellwether in Healthcare Services, consistently defying the law of large numbers, delivering revenue growth of +12% CAGR [compounded annual growth rate] and adjusted EPS growth of +16% CAGR over the past 10 years, even while pacing to generate over $370 billion in revenue in 2023E,” Fidel said. – CNBC’s Michael Bloom contributed reporting.
Aniket Pujari
6,159 PostsAniket Pujari is a passionate finance and technology enthusiast with a strong academic background in Financial Markets. Since 2015, he has been deeply immersed in the world of cryptocurrencies, blockchain technology, and global financial systems, building a wealth of knowledge and expertise in these rapidly evolving fields.
View All Posts